Flindokalner

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameFlindokalner
Drug Alias Name氟林卡那FlindokalnerumMaxiPostBMS-204352
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcium-activated potassium channel alpha/beta 1 agonistsKCNQ (Kv7) potassium channel agonists
TargetsCalcium-activated potassium channel alpha/beta 1KCNQ (Kv7) potassium channel
Therapy Area/IndicationsStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsStroke

Other Information

ATC CodeN/A
Related LinksKEGG